S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
The former chairman of the state-owned Bank of Beijing is being investigated for alleged corruption
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Arkhouse and Brigade up Macy's takeover offer to $6.6 billion following rejection of previous deal
Critical asset just had biggest fall on record (Ad)
OPEC+ production cuts deepen with extensions from Saudi Arabia, Russia and other oil giants
South Korea takes steps to suspend licenses of striking doctors after they refuse to end walkouts
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
The former chairman of the state-owned Bank of Beijing is being investigated for alleged corruption
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Arkhouse and Brigade up Macy's takeover offer to $6.6 billion following rejection of previous deal
Critical asset just had biggest fall on record (Ad)
OPEC+ production cuts deepen with extensions from Saudi Arabia, Russia and other oil giants
South Korea takes steps to suspend licenses of striking doctors after they refuse to end walkouts
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
The former chairman of the state-owned Bank of Beijing is being investigated for alleged corruption
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Arkhouse and Brigade up Macy's takeover offer to $6.6 billion following rejection of previous deal
Critical asset just had biggest fall on record (Ad)
OPEC+ production cuts deepen with extensions from Saudi Arabia, Russia and other oil giants
South Korea takes steps to suspend licenses of striking doctors after they refuse to end walkouts
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
The former chairman of the state-owned Bank of Beijing is being investigated for alleged corruption
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Arkhouse and Brigade up Macy's takeover offer to $6.6 billion following rejection of previous deal
Critical asset just had biggest fall on record (Ad)
OPEC+ production cuts deepen with extensions from Saudi Arabia, Russia and other oil giants
South Korea takes steps to suspend licenses of striking doctors after they refuse to end walkouts

DexCom (DXCM) Stock Price, News & Analysis

$121.74
+6.67 (+5.80%)
(As of 03/1/2024 ET)
Today's Range
$113.69
$122.23
50-Day Range
$114.22
$129.70
52-Week Range
$74.75
$139.55
Volume
4.53 million shs
Average Volume
3.25 million shs
Market Capitalization
$46.93 billion
P/E Ratio
92.93
Dividend Yield
N/A
Price Target
$134.64

DexCom MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.92 Rating Score
Upside/​Downside
10.6% Upside
$134.64 Price Target
Short Interest
Healthy
4.43% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.76
Upright™ Environmental Score
News Sentiment
0.78mentions of DexCom in the last 14 days
Based on 19 Articles This Week
Insider Trading
Selling Shares
$6.79 M Sold Last Quarter
Proj. Earnings Growth
26.44%
From $1.74 to $2.20 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.87 out of 5 stars

Medical Sector

29th out of 947 stocks

Surgical & Medical Instruments Industry

5th out of 95 stocks


DXCM stock logo

About DexCom Stock (NASDAQ:DXCM)

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

DXCM Stock Price History

DXCM Stock News Headlines

Wall Street is surprisingly most bullish on these 3 Nasdaq stocks
Analysts are gradually shifting toward underperforming, less prominent names to find the next big thing - including these three current Wall Street faves
Wall Street is surprisingly most bullish on these 3 Nasdaq stocks
NVIDIA is the best example. After soaring 239% last year, the semiconductor leader is up almost 50% year-to-date.
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
3 Nasdaq stocks likely to make big earnings splashes
Here we look at a few examples of high beta, high standard deviation Nasdaq-100 stocks that are poised to have volatile earnings moves in the near future.
DXCM Mar 2024 104.000 call
3 Telehealth Stocks With Room to Run in 2024
DXCM Jan 2026 170.000 call
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
DXCM Mar 2024 124.000 call
DXCM Mar 2024 139.000 call
Validea Detailed Fundamental Analysis - DXCM
Dexcom Announces Upcoming Conference Presentation
Dexcom Announces Upcoming Conference Presentation
DexCom (NASDAQ:DXCM) Sees Large Volume Increase
DXCM Jan 2026 140.000 call
DXCM Mar 2024 130.000 call
DXCM Mar 2024 121.000 call
DXCM Mar 2024 80.000 put
DXCM Mar 2024 114.000 call
DXCM Feb 2024 107.000 call
DexCom Inc EVP CFO Jereme Sylvain Sells Company Shares
See More Headlines
Receive DXCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DexCom and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/08/2024
Today
3/03/2024
Next Earnings (Estimated)
4/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:DXCM
CUSIP
25213110
Employees
9,600
Year Founded
1999

Price Target and Rating

Average Stock Price Target
$134.64
High Stock Price Target
$151.00
Low Stock Price Target
$100.00
Potential Upside/Downside
+10.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.92
Research Coverage
13 Analysts

Profitability

Net Income
$541.50 million
Pretax Margin
19.61%

Debt

Sales & Book Value

Annual Sales
$3.62 billion
Cash Flow
$2.07 per share
Book Value
$5.37 per share

Miscellaneous

Free Float
383,934,000
Market Cap
$46.93 billion
Optionable
Optionable
Beta
1.18

Social Links

The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report














DXCM Stock Analysis - Frequently Asked Questions

Should I buy or sell DexCom stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last year. There are currently 2 hold ratings, 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" DXCM shares.
View DXCM analyst ratings
or view top-rated stocks.

What is DexCom's stock price target for 2024?

13 brokerages have issued 12-month target prices for DexCom's stock. Their DXCM share price targets range from $100.00 to $151.00. On average, they predict the company's share price to reach $134.64 in the next twelve months. This suggests a possible upside of 10.6% from the stock's current price.
View analysts price targets for DXCM
or view top-rated stocks among Wall Street analysts.

How have DXCM shares performed in 2024?

DexCom's stock was trading at $124.09 on January 1st, 2024. Since then, DXCM shares have decreased by 1.9% and is now trading at $121.74.
View the best growth stocks for 2024 here
.

Are investors shorting DexCom?

DexCom saw a drop in short interest in the month of February. As of February 15th, there was short interest totaling 17,070,000 shares, a drop of 8.0% from the January 31st total of 18,560,000 shares. Based on an average daily volume of 2,970,000 shares, the short-interest ratio is presently 5.7 days.
View DexCom's Short Interest
.

When is DexCom's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our DXCM earnings forecast
.

How were DexCom's earnings last quarter?

DexCom, Inc. (NASDAQ:DXCM) announced its earnings results on Thursday, February, 8th. The medical device company reported $0.50 earnings per share for the quarter, beating the consensus estimate of $0.43 by $0.07. The medical device company earned $1.03 billion during the quarter, compared to analyst estimates of $1.02 billion. DexCom had a net margin of 14.95% and a trailing twelve-month return on equity of 28.31%. DexCom's revenue was up 26.9% on a year-over-year basis. During the same period in the previous year, the business earned $0.34 earnings per share.
Read the conference call transcript
.

When did DexCom's stock split?

DexCom shares split on Friday, June 10th 2022. The 4-1 split was announced on Friday, March 25th 2022. The newly created shares were distributed to shareholders after the closing bell on Thursday, June 9th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split.

What guidance has DexCom issued on next quarter's earnings?

DexCom updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $4.2 billion-$4.4 billion, compared to the consensus revenue estimate of $4.3 billion.

What is Kevin Sayer's approval rating as DexCom's CEO?

347 employees have rated DexCom Chief Executive Officer Kevin Sayer on Glassdoor.com. Kevin Sayer has an approval rating of 88% among the company's employees.

What other stocks do shareholders of DexCom own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), PayPal (PYPL), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), Salesforce (CRM), ServiceNow (NOW), Walt Disney (DIS), Trade Desk (TTD) and Shopify (SHOP).

Who are DexCom's major shareholders?

DexCom's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (11.53%), Baillie Gifford & Co. (4.28%), Capital Research Global Investors (3.97%), Sands Capital Management LLC (3.91%), Capital World Investors (2.41%) and Artisan Partners Limited Partnership (1.53%). Insiders that own company stock include Andrew K Balo, Andrew K Balo, Barbara Kahn, Barry J Regan, Bridgette P Heller, Chad Patterson, Jacob Steven Leach, Jay S Skyler, Jereme M Sylvain, Jereme M Sylvain, Kevin R Sayer, Kevin R Sayer, Mark G Foletta, Matthew Vincent Dolan, Michael Jon Brown, Nicholas Augustinos, Patrick Michael Murphy, Paul R Flynn, Paul R Flynn, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Sadie Stern, Shelly Ramasamy Selvaraj, Steven R Altman, Steven Robert Pacelli and Sumi Shrishrimal.
View institutional ownership trends
.

How do I buy shares of DexCom?

Shares of DXCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does DexCom have any subsidiaries?
The following companies are subsidiares of DexCom: DexCapital LLC, DexCom (Canada) Inc., DexCom (UK) Distribution Ltd., DexCom (UK) Intermediate Holdings Ltd., DexCom (UK) Ltd., DexCom Asia Pacific Operations PTE Ltd., DexCom Canada Co, DexCom Deutschland GmbH, DexCom International Ltd., DexCom Kommanditbolag, DexCom Operating Ltd., DexCom Philippines Inc, DexCom Suisse GmbH, Nintamed Handels GmbH, SweetSpot Diabetes Care Inc, The Glucose Program LLC, and TypeZero Technologies Inc.
Read More
This page (NASDAQ:DXCM) was last updated on 3/3/2024 by MarketBeat.com Staff